Published in Ther Clin Risk Manag on December 04, 2015
Richter's Syndrome with Hypercalcemia Induced by Tumor-Associated Production of Parathyroid Hormone-Related Peptide. Case Rep Oncol (2017) 0.75
A successful treatment of hypercalcemia with zoledronic acid in a 15-year-old boy with acute lymphoblastic leukemia. Ann Pediatr Endocrinol Metab (2016) 0.75
Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies. Case Rep Endocrinol (2017) 0.75
Mechanisms of bone metastasis. N Engl J Med (2004) 10.40
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
Hypercalcemia in malignant disease without evidence of bone destruction. Am J Med (1956) 4.51
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Clinical practice. Hypercalcemia associated with cancer. N Engl J Med (2005) 3.88
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther (2001) 3.59
Cellular and molecular mechanisms of action of bisphosphonates. Cancer (2000) 3.57
Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest (1996) 3.44
Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci U S A (1992) 3.01
Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med (1974) 2.97
Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med (1990) 2.76
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol (2001) 2.72
Hypercalcaemia--a hospital survey. Q J Med (1980) 2.50
Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med (1990) 2.43
Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med (2008) 2.23
Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab (2014) 2.17
Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol (2006) 2.12
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol (2007) 2.09
The hypercalcemia of malignancy: pathogenesis and management. Metabolism (1982) 2.01
Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol Rev (1996) 1.91
Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer (1993) 1.91
Rehydration in the treatment of severe hypercalcaemia. Q J Med (1981) 1.87
Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res (1994) 1.84
Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood (1993) 1.80
Management of acute hypercalcemia. N Engl J Med (1992) 1.79
Pseudohyperparathyroidism. Medicine (Baltimore) (1966) 1.70
Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood (2000) 1.69
Differential diagnosis of hypercalcemia. J Bone Miner Res (1991) 1.56
Vitamin D: metabolism. Endocrinol Metab Clin North Am (2010) 1.56
Bisphosphonate nephrotoxicity. Kidney Int (2008) 1.53
Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J (2006) 1.53
Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest (1990) 1.52
Parathyroid hormone-like proteins: biochemical responses and receptor interactions. Endocr Rev (1989) 1.48
Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab (2007) 1.39
Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J Bone Miner Res (2003) 1.31
Pancreatitis and primary hyperparathyroidism: forty cases. Aust N Z J Surg (1998) 1.29
Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med (1993) 1.23
Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia. Ann Intern Med (1989) 1.21
Incidence of hypercalcemia and malignant neoplasm. Arch Surg (1980) 1.15
Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia. Clin J Am Soc Nephrol (2012) 1.07
The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist (2011) 1.03
The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin Oncol (2001) 0.98
Molecular pharmacology of the calcitonin receptor. Receptors Channels (2002) 0.98
Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metab (1989) 0.97
Understanding hypercalcemia. Its metabolic basis, signs, and symptoms. Postgrad Med (2004) 0.96
Hypercalcemia in cancer patients: pathobiology and management. Horm Metab Res (2009) 0.96
Malignancy and concomitant primary hyperparathyroidism. J Surg Oncol (1988) 0.94
Survival in hypercalcaemic patients with cancer and co-existing primary hyperparathyroidism. Postgrad Med J (1995) 0.94
Hypercalcemia and ectopic secretion of parathyroid hormone by an ovarian carcinoma with rearrangement of the gene for parathyroid hormone. N Engl J Med (1990) 0.94
Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia. J Clin Endocrinol Metab (1996) 0.93
PTHrP-mediated hypercalcemia: causes and survival in 138 patients. J Clin Endocrinol Metab (2015) 0.91
Hypercalcemia in bronchogenic carcinoma. A prospective study of 200 patients. Ann Intern Med (1974) 0.91
Humoral hypercalcemia associated with gastric carcinoma secreting parathyroid hormone: a case report and review of the literature. Endocr J (2013) 0.88
Hypercalcaemia induced by excessive parathyroid hormone secretion in a patient with a neuroendocrine tumour. Nephrol Dial Transplant (2005) 0.86
Calcitonin as a drug. Ann Intern Med (1981) 0.86
Control of renal hemodynamics and glomerular filtration rate in chronic hypercalcemia. Role of prostaglandins, renin-angiotensin system, and calcium. J Clin Invest (1983) 0.84
Correction of hypercalcemia and hypophosphatemia by hemodialysis using a conventional, calcium-containing dialysis solution enriched with phosphorus. Am J Kidney Dis (1997) 0.84
1,25-dihydroxyvitamin D-mediated hypercalcemia in ovarian dysgerminoma. Pediatr Hematol Oncol (2008) 0.83
Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians. Clin Genitourin Cancer (2014) 0.83
Conventional treatment of hypercalcemia of malignancy. Am J Health Syst Pharm (2001) 0.83
Calcium free hemodialysis: an effective therapy in hypercalcemic crisis--report of 4 cases. Intensive Care Med (1989) 0.82
Parathyroid hormone expression in a patient with metastatic nasopharyngeal rhabdomyosarcoma and hypercalcemia. Endocrine (2005) 0.81
Calcium-free hemodialysis for the management of hypercalcemia. Nephron (1996) 0.81
Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy. Am J Kidney Dis (2013) 0.80
Malignant hypercalcemia--a hospital survey. Acta Med Scand (1986) 0.80
New insights in bone biology: unmasking skeletal effects of the extracellular calcium-sensing receptor. Sci Signal (2008) 0.80
Clinical utilization of cinacalcet in hypercalcemic conditions. Expert Opin Drug Metab Toxicol (2011) 0.79
Parathyroid hormone-related protein as a potential target of therapy for cancer-associated morbidity. Cancer (2000) 0.79
The effects of calcitonin in hypercalcemia in patients with malignancy. Cancer (1974) 0.79
Diagnostic approach to hypercalcemia: relevance of parathyroid hormone and parathyroid hormone-related protein measurements. Eur J Intern Med (2001) 0.79
Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. Clin Lymphoma Myeloma Leuk (2014) 0.78
Hypercalcemia of malignancy: pathophysiology and treatment. Bone (1992) 0.76